Addex Announces ADX10059 Phase IIa Acute Anxiety Data

Addex Announces ADX10059 Phase IIa Acute Anxiety Data


Geneva, Switzerland, 3 January 2008 – Allosteric modulation company Addex Pharmaceuticals (SWX: ADXN) announced today that ADX10059 did not reduce acute anticipatory anxiety in a small Phase IIa study in patients with dental anxiety. However, some signs of anxiolytic activity were observed. Development of ADX10059 for gastroesophageal reflux disease (GERD) and migraine is continuing as planned.

“Although ADX10059 did not demonstrate efficacy in this clinical model of acute anticipatory anxiety, we believe ADX10059 has potential for other types of human anxiety, especially where therapeutic administration of a longer duration is necessary,” said Charlotte Keywood, CMO of Addex. “We will complete analysis of the data from this study before announcing further plans for ADX10059 in the anxiety indication.” 

The study was a double-blind, placebo-controlled trial, conducted at specialist U.K. dental centers. It included 50 patients with moderately severe dental anxiety that underwent a routine dental procedure. Patients received a single 250 mg dose of ADX10059 or placebo 60 minutes prior to a dental procedure. Anxiety was measured at specific time points before, during and after the procedure using a subjective rating scale, called the Visual Analog Scale of anxiety (VAS anxiety). Skin conductance, an objective measure of the physiological response to stress and patient ratings of study medication effectiveness also were collected.

The primary endpoint, VAS anxiety at 60 minutes after dosing (immediately prior to the start of the dental procedure), did not show a statistical difference between ADX10059 and placebo (mean VAS 4.81 cm compared to 4.67 cm, respectively). Although VAS anxiety is a well recognized way to measure response to anti anxiety medications, it is a subjective measure and consequently can make interpretation of drug activity challenging, particularly in smaller studies.

Signs of anxiolytic activity were observed in the trial. Although the differences were not statistically significant, patients in the ADX10059 group had lower increases in skin conductance at all time points from 30 minutes post dose, suggesting a lower level of stress. In addition, patients rated ADX10059 as more effective, with 56% rating it as “good” or “excellent” compared to 30% of those who received placebo. Also, 15% of patients receiving ADX10059 rated it as “poor” compared to 39% of patients receiving placebo. Statistical analyses of the patient ratings are ongoing.

ADX10059 was generally well tolerated in the study and there were no serious adverse events.

ADX10059 is a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5). Fenobam, a product with a similar mechanism of action demonstrated efficacy in patients with generalized anxiety disorder after repeated administration in studies conducted in the 1980s*. 

“These data do not have any impact on the potential of ADX10059 in migraine or gastroesophageal reflux disease,” said Vincent Mutel, CEO of Addex. “We intend to start Phase IIb testing of ADX10059 in both GERD and migraine in mid-2008, as planned.” 

In preparation for the Phase IIb program, ADX10059 formulation work is nearing completion and the first galenic formulation of the product is expected to enter a confirmatory Phase I program around the end of the first quarter of 2008. An unformulated version of ADX10059 (i.e. the active pharmaceutical ingredient in capsule) met primary endpoints in separate Phase IIa proof of concept studies in GERD and migraine in 2007.

Addex also announced today, in a separate press release, a new licensing deal with Merck & Co. Inc. to develop ADX63365 to treat schizophrenia. A conference call and webcast for investors and analysts to discuss both announcements will be held later today. Slides will be made available on Addex’ website.
*Journal of Pharmacology and Experimental Therapeutics, 2005 Nov;315(2):711-21

About Addex 

Addex Pharmaceuticals discovers and develops allosteric modulators, an emerging class of small molecule therapeutic agents. Allosteric modulation may offer more sophisticated ways to normalize biological signaling compared to classical orthosteric agonist or antagonist drugs. Allosteric, literally translated from its Greek roots, means: other site. Thus, allosteric modulators bind receptors at sites that are distinct from the binding sites of classical small molecule orthosteric agonist and antagonist drugs.

The most advanced drug candidate, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients. Phase IIb testing is scheduled to start in both indications in mid-2008.

The Addex allosteric modulation discovery and development platform has been validated through collaborations with Merck & Co., Inc. and Johnson & Johnson.


Chris Maggos
Head of IR & Communications
Addex Pharmaceuticals
  +41 22 884 15 11     

Webcast & Conference call 

Title: Merck Deal and Phase IIa Anxiety Data
The webcast and slides will be available at: 
Teleconference for investors and analysts:
Date: 3 January 2008
Time: 17:00 ~ 18:00 CET (11:00 am ~ 12:00 pm EST)  
Dial-in numbers:    
  +41 91 610 56 00       (Europe)
  +44 207 107 0611      (UK) 
 +1 866 291 4166        (USA)     

A replay and transcript will be made available in the investor relations section of Addex’ website.


The foregoing release contains forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Pharmaceuticals Ltd, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Pharmaceuticals Ltd regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with allosteric modulators of mGluR4, mGluR2 or mGluR5 to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR4, mGluR2 or mGluR5 will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding  allosteric modulators of mGluR4, mGluR2 or mGluR5 could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.